Phil Vanek, PhD, GE Healthcare’s General Manager of Cell and Gene Therapy and Alliance for Regenerative Medicine (ARM) board member, sat down with In Vivo to discuss the company’s future plans and strategy for gene and cell therapy expansion. Tap into his views of the essential steps biopharma companies hoping to succeed in this area must undertake, from properly ad proactively addressing logistical issues, to effectively managing capital assets, to tips for attracting top talent, in this illuminating interview.